A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis
暂无分享,去创建一个
V. Meininger | W. Robberecht | P. Shaw | L. Lacomblez | J. Mora | T. Lenglet | A. Ludolph | J. Abitbol | V. Cuvier | R. Pruss | A. Ludolph | P. Shaw | J.-L. Abitbol | Jesús S. Mora | Pamela J. Shaw | R. M. Pruss | Vincent Meininger | V. Meininger
[1] O. Hardiman,et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial , 2013, The Lancet Neurology.
[2] L. Rubin,et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. , 2013, Cell stem cell.
[3] B. Pettmann,et al. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model , 2012, Neuropharmacology.
[4] G. Bennett,et al. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel , 2012, Neuroscience.
[5] V. Meininger,et al. Improving survival in a large French ALS center cohort , 2012, Journal of Neurology.
[6] V. Gribkoff,et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis , 2011, Nature Medicine.
[7] V. Meininger,et al. How can we improve clinical trials in amyotrophic lateral sclerosis? , 2011, Nature Reviews Neurology.
[8] P. Shaw,et al. Review: The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis , 2011, Neuropathology and applied neurobiology.
[9] M. Cudkowicz,et al. Emerging targets and treatments in amyotrophic lateral sclerosis , 2011, The Lancet Neurology.
[10] M. Carré,et al. Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. , 2010, Biochemical pharmacology.
[11] G. Bennett,et al. Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel , 2009, PAIN®.
[12] D. Schoenfeld,et al. The natural history of ALS is changing: Improved survival , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[13] Merit Cudkowicz,et al. ALS drug development: Reflections from the past and a way forward , 2008, Neurotherapeutics.
[14] B. Buisson,et al. Specific Antinociceptive Activity of Cholest-4-en-3-one, Oxime (TRO19622) in Experimental Models of Painful Diabetic and Chemotherapy-Induced Neuropathy , 2008, Journal of Pharmacology and Experimental Therapeutics.
[15] J. E. Kranz,et al. Design, power, and interpretation of studies in the standard murine model of ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[16] H. Mitsumoto,et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial , 2007, The Lancet Neurology.
[17] C. Henderson,et al. Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis , 2007, Journal of Pharmacology and Experimental Therapeutics.
[18] P. Kaufmann,et al. Pentoxifylline in ALS , 2006, Neurology.
[19] P. Shaw,et al. Apoptosis in amyotrophic lateral sclerosis—what is the evidence? , 2005, The Lancet Neurology.
[20] T. Conrad,et al. A clinical trial of creatine in ALS , 2004, Neurology.
[21] V. Meininger,et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[22] M. Swash,et al. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[23] J. Cedarbaum,et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.
[24] P. Leigh,et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.
[25] M. Swash,et al. Preclinical and subclinical events in motor neuron disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.
[26] P. Leigh,et al. What do people at risk for Alzheimer disease think about surrogate consent for research? , 2005, Neurology.
[27] P. Leigh,et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. , 1996, Lancet.